Sorafenib, another clinically approved drug inhibiting SLC7A11, can be used for GC [133], liver cancer [134–136], etc. Moreover, another type of FIN can induce ferroptosis by blocking the enzymatic activity of GPX4, such as RSL3, ML162, and ML210, thus achieving the inhibition of cancer [137, 138]. This evidence concerns the gene SLC7A11 and cancer.